You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Lindis biotech presents encouraging data from bladder cancer trial

Lindis Biotech has announced positive data from all three dose groups from its ongoing Catunibla phase 1 trial. The objective of developing the drug candidate is to reduce the rate of radical bladder removal as well as to decrease recurrence and progression rates.